Literature DB >> 9754313

Development and characterization of paromomycin-resistant Leishmania donovani promastigotes.

M Maarouf1, M T Adeline, M Solignac, D Vautrin, M Robert-Gero.   

Abstract

Paromomycin is an antileishmanial chemotherapeutic agent. Leishmania donovani promastigotes resistant to 800 microM of paromomycin were selected by increasing drug pressure and cloned. These promastigotes did not acquire multidrug resistance. Paromomycin resistance was stable in the absence of the drug in the culture. It remained stable also in amastigotes isolated after a passage in mice. Furthermore the resistant parasites were still infective to macrophages in vitro and for mice in vivo. A sensitive method to detect and to quantify intracellular paromomycin by HPLC was developed and allowed to show that the main mechanism of resistance seems to be due to decreased drug uptake probably as a consequence of altered membrane composition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754313     DOI: 10.1051/parasite/1998052167

Source DB:  PubMed          Journal:  Parasite        ISSN: 1252-607X            Impact factor:   3.000


  23 in total

Review 1.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.

Authors:  S Hendrickx; G Boulet; A Mondelaers; J C Dujardin; S Rijal; L Lachaud; P Cos; P Delputte; L Maes
Journal:  Parasitol Res       Date:  2014-03-11       Impact factor: 2.289

3.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

4.  In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.

Authors:  S Hendrickx; A Mondelaers; E Eberhardt; P Delputte; P Cos; L Maes
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

5.  Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Authors:  Vasundhra Bhandari; Shyam Sundar; Jean Claude Dujardin; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

7.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

Review 8.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 9.  Leishmaniasis: where are we and where are we heading?

Authors:  Santanu Sasidharan; Prakash Saudagar
Journal:  Parasitol Res       Date:  2021-04-07       Impact factor: 2.289

10.  Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.

Authors:  Sarah Hendrickx; Raquel Andrea Inocêncio da Luz; Vasundhra Bhandari; Kristel Kuypers; Craig D Shaw; Julien Lonchamp; Poonam Salotra; Katharine Carter; Shyam Sundar; Suman Rijal; Jean-Claude Dujardin; Paul Cos; Louis Maes
Journal:  PLoS Negl Trop Dis       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.